hero image
Elias Sayour - University of Florida. Gainesville, FL, US

Elias Sayour

Assistant Professor/M.D. | University of Florida

Gainesville, FL, UNITED STATES

Dr. Elias Saymour is an expert in pediatric oncology and hematology with a specialization in immunologic treatment of cancer.


Dr. Elias Sayour is the principal investigator of the RNA Engineering Laboratory within the Preston A. Wells, Jr. Center for Brain Tumor Therapy and UF Brain Tumor Immunotherapy Program. He is working to develop lipid-nanoparticles to train the immune system to fight cancer. Dr. Sayour's specialty is pediatric hematology-oncology.

Areas of Expertise (4)

Pediatric Oncology

mRNA Vaccines

Cancer Immunotherapy

Pediatric Cancer

Articles (3)

The current landscape of immunotherapy for pediatric brain tumors

Nature Cancer

Eugene I. Hwang, et al.


Pediatric central nervous system tumors are the most common solid malignancies in childhood, and aggressive therapy often leads to long-term sequelae in survivors, making these tumors challenging to treat. Immunotherapy has revolutionized prospects for many cancer types in adults, but the intrinsic complexity of treating pediatric patients and the scarcity of clinical studies of children to inform effective approaches have hampered the development of effective immunotherapies in pediatric settings.

view more

Optimizing T Cell-Based Therapy for Glioblastoma

Frontiers in immunology

Aida Karachi, et al.


Evading T cell surveillance is a hallmark of cancer. Patients with solid tissue malignancy, such as glioblastoma (GBM), have multiple forms of immune dysfunction, including defective T cell function. T cell dysfunction is exacerbated by standard treatment strategies such as steroids, chemotherapy, and radiation. Reinvigoration of T cell responses can be achieved by utilizing adoptively transferred T cells, including CAR T cells.

view more

Contemporary RNA Therapeutics for Glioblastoma

Neuromolecular medicine

Kaitlyn Melnick, et al.


Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM. RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability.

view more





Elias Sayour loading image